- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06295458
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait (Flicker w FOG)
This study aims to answer the question: to assess the safety, and tolerability of gamma light in Parkinson's disease (PD) patients with freezing of gait (FOG).
Parkinson's disease (PD) patients often experience a complex gait disorder known as Freezing of Gait (FOG). FOG is characterized by brief arrests of stepping when initiating gait, turning, and walking straight and patients describe it as their feet being "glued" to the floor. FOG in Parkinson's disease (PD) is a considerable public health burden worldwide. It is a poorly understood gait symptom that has potentially grave consequences as FOG is intermittent and unpredictable, a leading cause of falls with injury, and results in loss of independence. FOG is generally found to be associated with cognitive decline, particularly executive dysfunction which, in turn, has been associated with higher spinal fluid amyloid (Aβ42) levels in PD.
There is data linking amyloid to FOG. A previous study showed that the gamma light helped reduce some amyloid. The research team is studying if gamma light exposure for 1 hour daily is well tolerated. Also, does it have any effect on freezing of gait severity?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a sham-controlled study with one group receiving the sensory stimulation and the other receiving sham stimulation.
Exposure will be provided by wearing a pair of glasses and headphones. Both of these will be connected to a device that will provide light and sound during the daily 1-hour session.
Gamma light appeared in a previous study to have potential as a non-invasive, non-medication approach to reduce amyloid from the brain. This study will investigate if the link between amyloid and FOG can be changed and improve FOG.
Gamma is a short wavelength of light and/or sound between 25-140Hz. Previous research suggested that 40Hz can potentially activate cells in the brain to remove amyloid. Amyloid is a protein that forms in the spaces between nerve cells in the brain in diseases such as Alzheimer's and Parkinson's disease.
This study also has two optional parts. One option is to undergo two lumbar punctures at the baseline and Month 6 visits. The other option is to participate in a one-year extension of the study. Blood draws will be used to verify levodopa levels in the blood during both the ON and OFF Parkinson's disease medication states.
Optional lumbar punctures will be performed at baseline and 6 months to collect cerebrospinal fluid (CSF) samples which will be analyzed for change in amyloid levels before and after treatment. An electroencephalogram (EEG) will be utilized at the beginning of the study to evaluate the brain's response to the stimulus. Cognitive testing will be administered to capture any cognitive changes. Questionnaires used will provide any changes to the participant's self-evaluation.
The duration of the blinded portion is approximately 7 months. The optional extension portion will have two in-clinic visits at month 12 and month 18. Participants will be enrolled from the Emory University movement disorder clinic.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Barbara Sommerfeld, MSN, RN
- Phone Number: 404-712-6997
- Email: bsommer@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Emory Movement Disorders Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- PD Diagnosis by UK Brain Bank Criteria
- Hoehn & Yahr stage I-IV in the off-state
- FOG noted in medical history
- FOG confirmed visually by the examiner in the office
- PD that is levodopa-treated and responsive
- Able to manage 12 hours of "OFF" dopaminergic medication state
- Age 50-75 years
- Able to sign a consent document and willing to participate in all aspects of the study
Exclusion Criteria:
- A diagnosis of atypical parkinsonism including vascular parkinsonism
- Prior treatment with medications that cause Parkinsonism
- Stage V PD -unable to walk independently when OFF
- Absence of levodopa response
- Neurological or orthopedic disorders interfering with gait
- Dementia precluding completing study protocol including those meeting criteria for dementia with Lewy bodies
- Major depression based on the Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria
- Any medical problems that would preclude participation, including individuals with a history of migraines, tinnitus, or seizures because sensory stimuli can potentially exacerbate these conditions.
- Profound sensory loss as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Flicker Exposure (Treatment Group)
Participants will be instructed to take home the stimulation equipment.
Participants and their study partners (if applicable) will be trained on how to use the device before leaving the facility.
Each device case also includes an instruction document.
Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day.
Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
|
Flicker exposure via a light and sound device-based stimulation-provided sensory stimulation device.
The DAVID Delight Plus device consists of light-emitting goggles and sound-emitting headphones that are turned on and off with a repetition rate of 40 Hz connected to a controller operated by the participant or study partner (if the participant elects to have an optional study partner).
At the baseline visit, light and sound intensity levels (auditory: 0-80 dBA, visual: 0-1400 lux) will be programmed into each participant's controller based on their unique response to tolerance and EEG entrainment testing which occurred at screening.
The participant may not detect gamma-flicker frequency.
Other Names:
|
Sham Comparator: Control Group
Participants will receive sham stimulation.
Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day.
Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
|
Sham therapy will be provided in the same manner as the flicker light.
The difference is that it will be a constant light and sound from the same device instead of the 40hz light treatment and sound.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Adverse events
Time Frame: up to 6 months
|
Participants will document the occurrence of any adverse events that occur during the flicker exposure to evaluate the safety and tolerability.
|
up to 6 months
|
Number of participants compliant with the study procedures
Time Frame: up to 6 months
|
Compliance will be measured by the number of participants who adhere to the study procedures (at-home usage, monitored by the device, and manual log of daily operation by the participants and their study partners).
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale in participants with PD
Time Frame: Baseline and up to 6 months
|
Each participant with PD will be assessed at baseline and at 6 months in the practically defined off state and after a levodopa challenge with the MDS-UPDRS scale.
The MDS-UPDRS was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications.
It includes a motor evaluation and characterizes the extent and burden of disease.
Each Parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment.
The maximum total UPDRS score is 199, indicating the worst possible disability from PD.
The change in severity based on both measures will be compared between groups.
|
Baseline and up to 6 months
|
Change in the freezing of gait severity in participants with PD.
Time Frame: Baseline and up to 6 months
|
Each participant with PD will be assessed at baseline and at 6 months in the practically defined off state and after a levodopa challenge with MDS-UPDRS scale and in the motion capture laboratory to assess percent time with freezing during timed up and go tests.
The change in severity based on both measures will be compared between groups.
|
Baseline and up to 6 months
|
Change in subjective changes in FOG.
Time Frame: Baseline and 6 months
|
Participants will complete the New Freezing of Gait Questionnaire (N-FOGQ) to assess subjective changes in FOG.
The NFOG-Q is in essence a valid, self-reported questionnaire assessing the clinical aspects of freezing (frequency and duration) and its impact on quality of life when looking back during a period of 1 month.
The total score ranges between 0 and 28 points and requires a rating of FOG occurrence in both on or off-medication states.
Higher scores correspond to more severe FOG.
|
Baseline and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the effects of driving gamma on cerebrospinal fluid (CSF) amyloid levels in patients with PD-FOG
Time Frame: Baseline and 6 months
|
Participants will be given the option to have a lumbar puncture at baseline and month 6.
CSF levels of Alzheimer markers, AB42 amyloid, T-tau, and p-tau will be measured and the groups compared.
|
Baseline and 6 months
|
Change in the effects of driving gamma on cerebrospinal fluid (CSF) inflammatory markers levels in patients with PD-FOG
Time Frame: Baseline and 6 months
|
Participants will be given the option to have a lumbar puncture at baseline and month 6.
CSF levels of Alzheimer's inflammatory markers will be measured and the groups compared.
|
Baseline and 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stewart Factor, DO, Emory University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00006945
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on David Delight Plus Device
-
Behavioral Health of the Palm BeachesUnknownDepression | Insomnia | AnxietyUnited States
-
Emory UniversityGeorgia Institute of TechnologyCompleted
-
Zona Health, IncResearch & Development Concierge CompanyTerminatedHypertension, SystolicUnited States
-
University of SaskatchewanMemorial University of NewfoundlandEnrolling by invitation
-
Charite University, Berlin, GermanyCompletedSchizophrenia | Auditory Verbal HallucinationsGermany
-
RTI SurgicalCompletedIntervertebral Disc DegenerationBelgium
-
University Health Network, TorontoSociety of Anesthesia and Sleep MedicineCompleted
-
Cutting Edge SASRecruitingCataract | Surgery | IOLFrance
-
New York Presbyterian Brooklyn Methodist HospitalCompletedChronic Obstructive Pulmonary DiseaseUnited States